文献速递神经肿瘤

反应堆硼中子俘获治疗44例复发难治性高级别脑膜瘤长期随访

Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
PubMed 文献 · Neuro Oncol · 2022-01-01

该回顾性研究分析了2005—2019年44例复发难治性高级别脑膜瘤患者接受反应堆硼中子俘获治疗(BNCT)的疗效。BNCT后中位总生存29.6个月,中位无进展生存13.7个月,仅22.2%出现局部复发,显示较好的局部控制和生存获益。

要点

  • BNCT后中位总生存29.6个月,中位无进展生存13.7个月。
  • 随访影像36例中35例肿瘤缩小,局部复发仅22.2%。
  • WHO 2级与3级患者BNCT后生存差异显著(P=.0009)。

核心结论

  • 反应堆BNCT对复发难治性高级别脑膜瘤可实现较好的局部控制和生存获益。

研究设计与样本

  • 回顾性分析2005—2019年44例连续接受反应堆BNCT的复发难治性高级别脑膜瘤患者。

主要发现

  • BNCT后中位总生存29.6个月(95%CI:16.1-40.4),初诊后中位总生存98.4个月(95%CI:68.7-169.4)。
  • BNCT后中位随访26个月(范围6.4-103)。
  • 2级(20例)与3级(24例)患者BNCT后中位总生存分别为44.4个月(95%CI:27.4-未确定)和21.55个月(95%CI:10.6-30.6),P=.0009。
  • 36例BNCT后超过3个月随访影像中35例肿瘤缩小;36例BNCT后中位无进展生存13.7个月(95%CI:8.3-28.6)。
  • 2级与3级患者BNCT后中位无进展生存分别为24.3个月(95%CI:9.8-未确定)和9.4个月(95%CI:6.3-14.4),P=.0024;局部复发仅占22.2%。

临床怎么用

  • 对于复发难治性高级别脑膜瘤,尤其是放疗后复发患者,反应堆BNCT可作为局部控制与生存获益的治疗选择。

局限性

  • 本研究为回顾性分析,样本量44例,多数肿瘤体积较大且3级患者比例极高,可能影响预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade meningioma (HGM) is difficult to treat, and recurrent HGM after radiotherapy has an especially poor prognosis. We retrospectively analyzed the cases of 44 consecutive patients with recurrent and refractory HGM who were treated by reactor-based boron neutron capture therapy (BNCT). METHODS: In 2005-2019, we treated 44 recurrent and refractory HGMs by reactor-based BNCT. We analyzed the patients' tumor shrinkage, overall survival (OS) after initial diagnosis, OS after BNCT, progression-free survival (PFS) post-BNCT, and treatment failure patterns. RESULTS: The median OS (mOS) after BNCT and mOS after initial diagnosis were 29.6 (95% CI: 16.1-40.4) and 98.4 (95% CI: 68.7-169.4) months, respectively. The median follow-up after BNCT was 26 (6.4-103) months. The grade 2 (20 cases) and 3 (24 cases) post-BNCT mOS values were 44.4 (95% CI: 27.4-not determined) and 21.55 (10.6-30.6) months, respectively (P = .0009). Follow-up images were obtained from 36 cases at >3 months post-BNCT; 35 showed tumor shrinkage during the observation period. The post-BNCT median PFS (mPFS) of 36 cases was 13.7 (95% CI: 8.3-28.6) months. The post-BNCT mPFS values in patients with grade 2 and 3 disease were 24.3 (95% CI: 9.8-not determined) and 9.4 (6.3-14.4) months, respectively (P = .0024). Local recurrence was observed in only 22.2% of cases. These results showed good local tumor control and prolonged survival for recurrent HGM cases. CONCLUSIONS: Most of these cases had relatively large tumor volumes. The proportion of grade 3 patients was extremely high. Our patients thus seemed to have poor prognoses. Nevertheless, reactor-based BNCT exerted relatively good local control and favorable survival for recurrent and refractory HGMs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Takai S, Wanibuchi M, Kawabata S, et al. Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol. 2022. PMID: 33984146. doi:10.1093/neuonc/noab108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。